Cannabis Use in Hospitalized Patients with Chronic Pain.
Cannabinoids
Cannabis
Chronic pain
Opioid-related disorders
Prevalence
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
21
04
2020
pubmed:
8
7
2020
medline:
9
2
2021
entrez:
8
7
2020
Statut:
ppublish
Résumé
To date, no study has reported the prevalence of cannabis use in chronic pain patients. The aim of this study is to investigate the trends in cannabis use among chronic pain in-patients from 2011 to 2015 in the USA. Patients were identified from the National Inpatient Sample (NIS) database using the International Classification of Diseases, Ninth and Tenth Revision, diagnosis codes for chronic pain and cannabis use. Annual estimates and trends were determined for cannabis use, patient characteristics, cannabis use among subgroups of chronic pain conditions, cost, length of stay, and associated discharge diagnosis. Between 2011 to 2015, a total of 247,949 chronic pain patients were cannabis users, increasing from 33,189 to 72,115 (P < 0.001). There were upward trends of cannabis use in females (38.7-40.7%; P = 0.03), Medicare insured patients (32.7-40.4%; P < 0.01), patients with lowest annual household income (36.1-40.9%; P = 0.02), patients aged 45-64 years (45.9-49.2%; P < 0.001), and patients with tobacco use disorder (63.8-72.4%; P < 0.0001). Concurrently, cannabis use decreased among patients with opioid use disorder (23.8-19.9%; P < 0.001). Cannabis use increased from 2011 to 2015 in patients with chronic regional pain syndrome, trauma, spondylosis, and failed back surgery syndrome. Adjusted total hospitalization cost increased from $31,271 ($1333) in 2011 to $38,684 ($946) in 2015 (P < 0.001). Cannabis use increased substantially from 2011 to 2015, while the rates of cannabis use in opioid users down-trended simultaneously. Disparities in cannabis use among subgroups should be explored further.
Identifiants
pubmed: 32632850
doi: 10.1007/s12325-020-01416-9
pii: 10.1007/s12325-020-01416-9
pmc: PMC7370966
doi:
Substances chimiques
Medical Marijuana
0
Types de publication
Journal Article
Review
Langues
eng
Pagination
3571-3583Références
Tsang A, Von Korff M, Lee S, et al. Common chronic pain conditions in developed and developing countries: gender and age differences and comorbidity with depression-anxiety disorders. J Pain. 2008;9(10):883–91.
pubmed: 18602869
doi: 10.1016/j.jpain.2008.05.005
Degenhardt L, Lintzeris N, Campbell G, et al. Experience of adjunctive cannabis use for chronic non-cancer pain: findings from the Pain and Opioids IN Treatment (POINT) study. Drug Alcohol Depend. 2015;147:144–50.
pubmed: 25533893
doi: 10.1016/j.drugalcdep.2014.11.031
Chou SP, Zhang H, Jung J, Roger P. Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiatry. 2015;72(12):1235–42.
pubmed: 26502112
pmcid: 5037576
doi: 10.1001/jamapsychiatry.2015.1858
United Nations Office of Drug Control and Crime Prevention. World Drug Report; 2016.
Wagner FA, Anthony JC. From first drug use to drug dependence; developmental periods of risk for dependence upon marijuana, cocaine, and alcohol. Neuropsychopharmacology. 2002;26(4):479–88.
pubmed: 11927172
doi: 10.1016/S0893-133X(01)00367-0
Martel MO, Shir Y, Ware MA. Substance-related disorders: a review of prevalence and correlates among patients with chronic pain. Prog Neuro-Psychopharmacol Biol Psychiatry. 2017;87:245–54.
doi: 10.1016/j.pnpbp.2017.06.032
Fergusson DM, Boden JM, Horwood LJ. Cannabis use and other illicit drug use: testing the cannabis gateway hypothesis. Addiction. 2006;101(4):556–69.
pubmed: 16548935
doi: 10.1111/j.1360-0443.2005.01322.x
National Academies of Sciences, Engineering and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC; 2017.
Lévesque A, Le Foll B. when and how to treat possible cannabis use disorder. Med Clin N Am. 2018;102(4):667–81.
pubmed: 29933822
doi: 10.1016/j.mcna.2018.02.009
AHRQ. HCUP Nationwide Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP). Rockville.
Rumalla K, Reddy AY, Mittal MK. Recreational marijuana use and acute ischemic stroke: a population-based analysis of hospitalized patients in the United States. J Neurol Sci. 2016;364:191–6.
pubmed: 26874461
doi: 10.1016/j.jns.2016.01.066
Rumalla K, Reddy AY, Mittal MK. Association of recreational marijuana use with aneurysmal subarachnoid hemorrhage. J Stroke Cerebrovasc Dis. 2016;25(2):452–60.
pubmed: 26708529
doi: 10.1016/j.jstrokecerebrovasdis.2015.10.019
Reinarman C, Nunberg H, Lanthier F, Heddleston T. Who are medical marijuana patients? Population characteristics from nine California assessment clinics. J Psychoactive Drugs. 2011;43(2):128–35.
pubmed: 21858958
doi: 10.1080/02791072.2011.587700
Ware MA, Adams H, Guy GW. The medicinal use of cannabis in the UK: results of a nationwide survey. Int J Clin Pract. 2005;59(3):291–5.
pubmed: 15857325
doi: 10.1111/j.1742-1241.2004.00271.x
Pacula RL, Jacobson M, Maksabedian EJ. In the weeds: a baseline view of cannabis use among legalizing states and their neighbours. Addiction. 2016;111(6):973–80.
pubmed: 26687431
pmcid: 5216038
doi: 10.1111/add.13282
StataCorp. Stata. 2016.
Boehnke KF, Litinas E, Clauw DJ. Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. J Pain. 2016;17(6):739–44.
pubmed: 27001005
doi: 10.1016/j.jpain.2016.03.002
Haroutounian S, Ratz Y, Ginosar Y, et al. The effect of medicinal cannabis on pain and quality-of-life outcomes in chronic pain: a prospective open-label study. Clin J Pain. 2016;32(12):1036–43.
pubmed: 26889611
doi: 10.1097/AJP.0000000000000364
Manzanares J, Julian M, Carrascosa A. Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr Neuropharmacol. 2006;4(3):239–57.
pubmed: 18615144
pmcid: 2430692
doi: 10.2174/157015906778019527
Miller RJ, Miller RE. Is cannabis an effective treatment for joint pain? Clin Exp Rheumatol. 2017;35 Suppl 1(5):59–67.
doi: 10.1007/s10067-016-3468-6
Baron EP. Medicinal properties of cannabinoids, terpenes, and flavonoids in cannabis, and benefits in migraine, headache, and pain: an update on current evidence and cannabis science. Headache J Head Face Pain. 2018;58(7):1139–86.
doi: 10.1111/head.13345
Wallace JL, Flannigan KL, McKnight W, Wang L, Ferraz JGP, Tuitt D. Pro-resolution, protective and anti-nociceptive effects of a cannabis extract in the rat gastrointestinal tract. J Physiol Pharmacol. 2013;64(2):167–75.
pubmed: 23756391
Oláh A, Tóth BI, Borbíró I, et al. Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. J Clin Investig. 2014;124(9):3713–24.
pubmed: 25061872
doi: 10.1172/JCI64628
Blyth FM, March LM, Brnabic AJ, Jorm LR, Williamson M, Cousins MJ. Chronic pain in Australia: a prevalence study. Pain. 2001;89(2–3):127–34.
pubmed: 11166468
doi: 10.1016/S0304-3959(00)00355-9
Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10(4):287.
pubmed: 16095934
doi: 10.1016/j.ejpain.2005.06.009
Moulin DE, Clark AJ, Speechley M, Morley-Forster PK. Chronic pain in Canada—prevalence, treatment, impact and the role of opioid analgesia. Pain Res Manag. 2002;7(4):179–84.
pubmed: 12518174
doi: 10.1155/2002/323085
Hill KP, Palastro MD. Medical cannabis for the treatment of chronic pain and other disorders: misconceptions and facts. Polish Arch Intern Med. 2017;127(11):785–9.
Baron EP, Lucas P, Eades J, Hogue O. Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort. J Headache Pain. 2018;19(1):37.
pubmed: 29797104
pmcid: 5968020
doi: 10.1186/s10194-018-0862-2
Hill KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. JAMA. 2015;313(24):2474–83.
pubmed: 26103031
doi: 10.1001/jama.2015.6199
Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE. Monitoring the future national results on adolescent drug use: overview of key findings, 2012; 2013.
Center for Behavioral Health Statistics and Quality. National Survey on Drug Use and Health. Rockville; 2013.
Vin-Raviv N, Akinyemiju T, Meng Q, Sakhuja S, Hayward R. Marijuana use and inpatient outcomes among hospitalized patients: analysis of the nationwide inpatient sample database. Cancer Med. 2017;6(1):320–9.
pubmed: 27891823
doi: 10.1002/cam4.968
Zulman DM, Pal Chee C, Wagner TH, et al. Multimorbidity and healthcare utilisation among high-cost patients in the US Veterans Affairs Health Care System. BMJ Open. 2015;5(4):e007771.
pubmed: 25882486
pmcid: 4401870
doi: 10.1136/bmjopen-2015-007771
Cortaredona S, Ventelou B. The extra cost of comorbidity: multiple illnesses and the economic burden of non-communicable diseases. BMC Med. 2017;15(1):216.
pubmed: 29221453
pmcid: 5723100
doi: 10.1186/s12916-017-0978-2
Berthelsen CL. Evaluation of coding data quality of the HCUP National Inpatient Sample. Top Health Inf Manag. 2000;21(2):10–23.